$25 Million Boost—What’s Next for Pharmazz’s Revolutionary Stroke Drug?

Unknown Apr 02, 2026 1,050 Views

Pharmazz Inc. has received a $25 million strategic equity investment from Sun Pharmaceutical Industries Ltd., strengthening their partnership in neurology and critical care drug development. This funding will support Phase 3 clinical trials for sovateltide, a promising therapy for acute cerebral...